Ken Frazier, AP Images

It's not just about Keytru­da, Mer­ck in­sists, as it carves out as­sets worth $6.5B in­to new com­pa­ny

As sales of Mer­ck’s flag­ship ther­a­py Keytru­da grow from strength to strength — the New Jer­sey drug­mak­er is spin­ning off its women’s health, lega­cy brands, and biosim­i­lar drugs in­to a new com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.